These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 20530765

  • 1. Who should get the HPV vaccine? Usage expands amid debate.
    Peres J.
    J Natl Cancer Inst; 2010 Jun 16; 102(12):838-40. PubMed ID: 20530765
    [No Abstract] [Full Text] [Related]

  • 2. Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    Coupé VM, Meijer CJ, Berkhof J.
    J Natl Cancer Inst; 2010 Mar 03; 102(5):358; author reply 358. PubMed ID: 19861306
    [No Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM, van Ballegooijen M, Habbema JD.
    J Natl Cancer Inst; 2009 Aug 05; 101(15):1083-92. PubMed ID: 19571256
    [Abstract] [Full Text] [Related]

  • 4. Assessing the HPV vaccine: researchers confront complex interplay of factors.
    Tuma RS.
    J Natl Cancer Inst; 2009 Apr 01; 101(7):444-5. PubMed ID: 19318636
    [No Abstract] [Full Text] [Related]

  • 5. Primary and secondary prevention of cervical cancer--opportunities and challenges.
    Markowitz LE, Unger ER, Saraiya M.
    J Natl Cancer Inst; 2009 Apr 01; 101(7):439-40. PubMed ID: 19318638
    [No Abstract] [Full Text] [Related]

  • 6. Merck hopes to extend gardasil vaccine to men.
    Chitale R.
    J Natl Cancer Inst; 2009 Feb 18; 101(4):222-3. PubMed ID: 19211446
    [No Abstract] [Full Text] [Related]

  • 7. A brief history of economic evaluation for human papillomavirus vaccination policy.
    Beutels P, Jit M.
    Sex Health; 2010 Sep 18; 7(3):352-8. PubMed ID: 20719227
    [Abstract] [Full Text] [Related]

  • 8. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.
    Julius JM, Ramondeta L, Tipton KA, Lal LS, Schneider K, Smith JA.
    Pharmacotherapy; 2011 Mar 18; 31(3):280-97. PubMed ID: 21361739
    [Abstract] [Full Text] [Related]

  • 9. Response: Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    Rozenbaum MH, Boersma C.
    J Natl Cancer Inst; 2010 Mar 03; 102(5):358-9; author reply 359-60. PubMed ID: 20229619
    [No Abstract] [Full Text] [Related]

  • 10. Quadrivalent human papillomavirus vaccine.
    Barr E, Tamms G.
    Clin Infect Dis; 2007 Sep 01; 45(5):609-7. PubMed ID: 17682997
    [Abstract] [Full Text] [Related]

  • 11. The economic impact of HPV vaccines: not just cervical cancer.
    Myers ER.
    Am J Obstet Gynecol; 2008 May 01; 198(5):487-8. PubMed ID: 18455522
    [No Abstract] [Full Text] [Related]

  • 12. Who should get the HPV vaccine?
    Pichichero ME.
    J Fam Pract; 2007 Mar 01; 56(3):197-202. PubMed ID: 17343808
    [No Abstract] [Full Text] [Related]

  • 13. HPV prevention update. New vaccine offers additional options.
    Klisz C, Kaplan C.
    Adv Nurse Pract; 2009 Nov 01; 17(11):28-9, 54. PubMed ID: 20014688
    [No Abstract] [Full Text] [Related]

  • 14. For cancers caused by HPV, two vaccines were just the beginning.
    Peres J.
    J Natl Cancer Inst; 2011 Mar 02; 103(5):360-2. PubMed ID: 21357595
    [No Abstract] [Full Text] [Related]

  • 15. Cost-utility analysis of vaccination against HPV in Israel.
    Ginsberg GM, Fisher M, Ben-Shahar I, Bornstein J.
    Vaccine; 2007 Sep 17; 25(37-38):6677-91. PubMed ID: 17706844
    [Abstract] [Full Text] [Related]

  • 16. Introducing HPV vaccine in developing countries--key challenges and issues.
    Agosti JM, Goldie SJ.
    N Engl J Med; 2007 May 10; 356(19):1908-10. PubMed ID: 17494923
    [No Abstract] [Full Text] [Related]

  • 17. Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
    Mennini FS, Giorgi Rossi P, Palazzo F, Largeron N.
    Gynecol Oncol; 2009 Feb 10; 112(2):370-6. PubMed ID: 19041125
    [Abstract] [Full Text] [Related]

  • 18. Human papillomavirus vaccines.
    Satyaprakash A, Creed R, Ravanfar P, Mendoza N.
    Dermatol Ther; 2009 Feb 10; 22(2):150-7. PubMed ID: 19335726
    [Abstract] [Full Text] [Related]

  • 19. Lessons from the failure of human papillomavirus vaccine state requirements.
    Schwartz JL, Caplan AL, Faden RR, Sugarman J.
    Clin Pharmacol Ther; 2007 Dec 10; 82(6):760-3. PubMed ID: 17971822
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of human papilloma virus vaccination in Iceland.
    Oddsson K, Johannsson J, Asgeirsdottir TL, Gudnason T.
    Acta Obstet Gynecol Scand; 2009 Dec 10; 88(12):1411-6. PubMed ID: 19900074
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.